344 related articles for article (PubMed ID: 15536545)
1. Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging.
Chen YC; Choi JK; Andersen SL; Rosen BR; Jenkins BG
Psychopharmacology (Berl); 2005 Aug; 180(4):705-15. PubMed ID: 15536545
[TBL] [Abstract][Full Text] [Related]
2. Dopaminergic response to graded dopamine concentration elicited by four amphetamine doses.
Ren J; Xu H; Choi JK; Jenkins BG; Chen YI
Synapse; 2009 Sep; 63(9):764-72. PubMed ID: 19484725
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic neuroimaging of the ontogeny of dopamine receptor function.
Chen YI; Choi JK; Xu H; Ren J; Andersen SL; Jenkins BG
Dev Neurosci; 2010 Jul; 32(2):125-38. PubMed ID: 20523024
[TBL] [Abstract][Full Text] [Related]
4. Effects of the D(3) dopamine receptor antagonist, U99194A, on brain stimulation and d-amphetamine reward, motor activity, and c-fos expression in ad libitum fed and food-restricted rats.
Carr KD; Yamamoto N; Omura M; Cabeza de Vaca S; Krahne L
Psychopharmacology (Berl); 2002 Aug; 163(1):76-84. PubMed ID: 12185403
[TBL] [Abstract][Full Text] [Related]
5. Quinpirole-induced 50 kHz ultrasonic vocalization in the rat: role of D2 and D3 dopamine receptors.
Brudzynski SM; Komadoski M; St Pierre J
Behav Brain Res; 2012 Jan; 226(2):511-8. PubMed ID: 22015714
[TBL] [Abstract][Full Text] [Related]
6. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ
J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181
[TBL] [Abstract][Full Text] [Related]
7. Mapping the effects of the selective dopamine D2/D3 receptor agonist quinelorane using pharmacological magnetic resonance imaging.
Ireland MD; Lowe AS; Reavill C; James MF; Leslie RA; Williams SC
Neuroscience; 2005; 133(1):315-26. PubMed ID: 15893653
[TBL] [Abstract][Full Text] [Related]
8. Selective dopamine D(3) receptor antagonist SB-277011-A potentiates phMRI response to acute amphetamine challenge in the rat brain.
Schwarz A; Gozzi A; Reese T; Bertani S; Crestan V; Hagan J; Heidbreder C; Bifone A
Synapse; 2004 Oct; 54(1):1-10. PubMed ID: 15300879
[TBL] [Abstract][Full Text] [Related]
9. Sex differences in nicotine sensitization and conditioned hyperactivity in adolescent rats neonatally treated with quinpirole: role of D2 and D3 receptor subtypes.
Sheppard B; Lehmann J; Cope ZA; Brown RW
Behav Neurosci; 2009 Dec; 123(6):1296-308. PubMed ID: 20001113
[TBL] [Abstract][Full Text] [Related]
10. Mapping interactions between dopamine and adenosine A2a receptors using pharmacologic MRI.
Chen YI; Choi JK; Jenkins BG
Synapse; 2005 Feb; 55(2):80-8. PubMed ID: 15529335
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of amphetamine-induced stereotyped behaviors during the acute response: role of D1 and D2 dopamine receptors.
Kuczenski R; Segal DS
Brain Res; 1999 Mar; 822(1-2):164-74. PubMed ID: 10082894
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D2-receptors regulate neurotensin release from nucleus accumbens and striatum as measured by in vivo microdialysis.
Wagstaff JD; Gibb JW; Hanson GR
Brain Res; 1996 May; 721(1-2):196-203. PubMed ID: 8793101
[TBL] [Abstract][Full Text] [Related]
13. A dopamine partial agonist and antagonist block amphetamine self-administration in a progressive ratio schedule.
Izzo E; Orsini C; Koob GF; Pulvirenti L
Pharmacol Biochem Behav; 2001 Apr; 68(4):701-8. PubMed ID: 11526967
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic modulation of nitric oxide synthase activity in subregions of the rat nucleus accumbens.
Hoque KE; West AR
Synapse; 2012 Mar; 66(3):220-31. PubMed ID: 22034069
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D2 receptor-dependent modulation of striatal NO synthase activity.
Sammut S; Bray KE; West AR
Psychopharmacology (Berl); 2007 Apr; 191(3):793-803. PubMed ID: 17206493
[TBL] [Abstract][Full Text] [Related]
16. Evidence to suggest that agonist modulation of hyperlocomotion is via post-synaptic dopamine D2 or D3 receptors.
Thorn L; Ashmeade TE; Storey VJ; Routledge C; Reavill C
Neuropharmacology; 1997 Jun; 36(6):787-92. PubMed ID: 9225306
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the locomotor activating effects of the noncompetitive NMDA receptor antagonist MK801 by dopamine D2/3 receptor agonists in mice.
Cook CD; Newman JL; Winfree JC; Beardsley PM
Pharmacol Biochem Behav; 2004 Feb; 77(2):309-18. PubMed ID: 14751459
[TBL] [Abstract][Full Text] [Related]
18. Excitation of type II anterior caudate neurons by stimulation of dopamine D3 receptors.
Piercey MF; Hyslop DK; Hoffmann WE
Brain Res; 1997 Jul; 762(1-2):19-28. PubMed ID: 9262154
[TBL] [Abstract][Full Text] [Related]
19. D1 and D2 dopamine receptor mediation of amphetamine-induced acetylcholine release in nucleus accumbens.
Keys AS; Mark GP
Neuroscience; 1998 Sep; 86(2):521-31. PubMed ID: 9881866
[TBL] [Abstract][Full Text] [Related]
20. Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593.
Acri JB; Thompson AC; Shippenberg T
Synapse; 2001 Mar; 39(4):343-50. PubMed ID: 11169785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
